+

US20060105006A1 - Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss - Google Patents

Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss Download PDF

Info

Publication number
US20060105006A1
US20060105006A1 US11/331,011 US33101106A US2006105006A1 US 20060105006 A1 US20060105006 A1 US 20060105006A1 US 33101106 A US33101106 A US 33101106A US 2006105006 A1 US2006105006 A1 US 2006105006A1
Authority
US
United States
Prior art keywords
composition
hair
inhibitor
amount
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/331,011
Inventor
Francoise Jarrousse
Yann Mahe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to US11/331,011 priority Critical patent/US20060105006A1/en
Publication of US20060105006A1 publication Critical patent/US20060105006A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention relates to the use, in or for the preparation of a composition, as active principle in a physiologically acceptable medium, of an effective amount of at least one metalloprotease inhibitor, or of any functional biological equivalent, which is intended to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • the growth and renewal of the hair are mainly determined by the activity of the hair follicles and by their dermo-epidermal environment. Their activity is cyclic and essentially comprises three phases, i.e. the anagenic phase, the catagenic phase and the telogenic phase.
  • the active anagenic phase or growth phase which lasts for several years and during which the hair gets longer, is followed by a very short and transient catagenic phase which lasts a few weeks, and then comes a rest phase, known as the telogenic phase, which lasts a few months.
  • the hair falls out and another cycle begins.
  • the head of hair is thus under constant renewal, and out of the approximately 150,000 hairs which make up a head of hair, at any given moment, approximately 10% of them are at rest and will thus be replaced within a few months.
  • This alopecia is essentially due to a disruption in hair renewal which leads, in a first stage, to an acceleration of the frequency of the cycles, at the expense of the quality of the hair and then at the expense of its quantity.
  • a gradual depletion of the head of hair takes place by regression of the so-called “terminal” hairs at the downy stage. Regions are preferentially affected, in particular the temples or frontal bulbs and the back of the head in men, while in women diffuse alopecia of the vertex is observed.
  • a metalloprotease inhibitor or any functional biological equivalent, makes it possible to induce and/or stimulate the growth of head hair or other hairs, and/or to reduce their loss in an effective manner.
  • MMPs Metalloproteases
  • endoproteases which contain a zinc atom co-ordinated to 3 cysteine residues and one methionine residue in their active site and which degrade the macromolecular components of the extracellular matrix and the basal sheets at neutral pH (collagen, elastin, etc.).
  • endoproteases which contain a zinc atom co-ordinated to 3 cysteine residues and one methionine residue in their active site and which degrade the macromolecular components of the extracellular matrix and the basal sheets at neutral pH (collagen, elastin, etc.).
  • These enzymes which are very widely distributed in the living world, are present, but weakly expressed, in normal physiological situations such as organ growth and tissue renewal. However, their overexpression in man and their activation are associated with many processes which involve the destruction and remodelling of the matrix. This entails, for example, an uncontrolled resorption of the extracellular matrix.
  • Metalloproteases are produced and secreted in an inactive zymogenic form (pro-enzyme). These zymogenic forms are then activated in the extracellular environment by the removal of a propeptide region. The members of this family can activate each other.
  • Regulation of the activity of MMPs thus takes place at the level of the expression of the genes (transcription and translation), at the level of the activation of the zymogenic form, or at the level of the local control of the active forms.
  • MMPs The main regulators of the activity of MMPs are the tissue inhibitors of metalloproteases, or TIMPs.
  • TIMPs tissue inhibitors of metalloproteases
  • the expression of MMPs is also modulated by growth factors, cytokines, oncogenic products (ras, jun) or matrix constituents.
  • the metalloprotease family consists of several well-defined groups based on their resemblances in terms of substrate specificity and structure (see Woessner J. F., Faseb Journal, vol. 5, 1991, 2145).
  • collagenases intended to degrade fibrillar collagens (MMP-1 or interstitial collagenase, MMP-8 or neutrophil collagenase, and MMP-13 or collagenase 3), gelatinases which degrade type IV collagen or any form of denatured collagen (MMP-2 or gelatinase A (72 kDa), MMP-9 or gelatinase B (92 kDa)), stromelysins whose broad spectrum of activity applies to extracellular matrix proteins such as glycoproteins (fibronectin, laminin), proteoglycans, etc. or alternatively membrane metalloproteases.
  • hair follicles pass from a low-level location in the dermis in the anagenic phase, to a high-level location in the dermis during the telogenic phase.
  • This movement should be accompanied by a change in the extracellular matrix which allows the migration of the follicle, this change possibly being due to an expression of the MMPs, bringing about a controlled degradation of the said extracellular matrix.
  • cytokines and growth factors have an influence on the hair cycle.
  • epidermal growth factor promotes the in vitro transition from the anagenic phase to the catagenic phase (formation of a “club” structure characteristic of the catagenic phase), this being the phase which precedes the loss of the head hairs or other hairs. It is also known, as the Applicant has demonstrated, that there is an inflammatory phase in alopecia.
  • MMPs and particularly MMP-9 can be induced by interleukin-1 and/or EGF, in particular in the fibroblasts of the dermal papillae.
  • the Applicant thus proposes the use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • the invention relates to the use, in or for the preparation of a composition, of an effective amount of at least one metalloprotease inhibitor or of any functional biological equivalent, which is intended to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • peptides one biological equivalent of which may be a peptide in which at least one amino acid residue has been replaced with another amino acid having a similar hydropathic index.
  • metaloprotease inhibitor means any molecule capable of regulating the activity of MMPs either at the level of the expression of the genes (transcription and translation) or at the level of the activation of the zymogenic form of MMPs, or alternatively at the level of the local control of the active forms.
  • the main regulators of the activity of MMPs are natural molecules present in the tissues, known as tissue inhibitors of metalloproteases, or TIMPs.
  • inhibitors may also be known chemical molecules such as, for example, hydroxamic acid derivatives, cation-chelating agents, growth factors, cytokines, oncogenic products (ras, jun) or matrix constituents.
  • tissue inhibitors of metalloproteases such as, for example, the peptides known in the prior art under the names TIMP-1, TIMP-2, TIMP-3 and TIMP-4 (Woessner J. F., Faseb Journal, 1991) are preferably used.
  • the invention relates more particularly to the use, in or for the preparation of a composition, of an effective amount of at least one tissue inhibitor of metalloproteases (TIMP) or of any functional biological equivalent, the inhibitor or the composition being intended to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • TIMP tissue inhibitor of metalloproteases
  • TIMP-1 tissue inhibitors of metalloproteases.
  • TIMP-2 tissue inhibitors of metalloproteases.
  • TIMP-3 tissue inhibitors of metalloproteases.
  • the metalloprotease inhibitors can be used alone or as a mixture.
  • the form of the protection should obviously be a biologically compatible form.
  • Many biologically compatible forms of protection may be envisaged, such as, for example, acylation or acetylation of the amino-terminal end or amidation of the carboxy-terminal end.
  • the invention relates to a use as defined above, characterized in that the metalloprotease inhibitor is in a protected or unprotected form.
  • a protection based either on the acylation or acetylation of the amino-terminal end, or on the amidation of the carboxy-terminal end, or alternatively on both approaches, is preferably used according to the invention.
  • the amount of metalloprotease inhibitor which can be used according to the invention obviously depends on the desired effect and should be in an amount which is effective to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • the amount of metalloprotease inhibitor which can be used according to the invention may range, for example from 0.01% to 5% and preferably from 0.05% to 2% relative to the total weight of the composition.
  • the composition is preferably a cosmetic composition.
  • composition according to the invention can be administered enterally or parenterally. Preferably, via the parenteral route, the composition is administered topically.
  • the physiologically acceptable medium in which the peptide is used according to the invention may be anhydrous or aqueous.
  • anhydrous medium means a solvent medium containing less than 1% water. This medium may consist of a solvent or a mixture of solvents chosen more particularly from C 2 -C 4 lower alcohols such as ethyl alcohol, alkylene glycols such as propylene glycol, and alkylene glycol alkyl ethers or dialkylene glycol alkyl ethers, the alkyl or alkylene radicals of which contain from 1 to 4 carbon atoms.
  • aqueous medium means a medium consisting of water or of a mixture of water and another physiologically acceptable solvent, chosen in particular from the organic solvents mentioned above. In this last case, when these other solvents are present, they represent approximately 5% to 95% by weight of the composition.
  • the physiologically acceptable medium may contain other adjuvants usually used in cosmetics, such as surfactants, thickeners or gelling agents, cosmetic agents, preserving agents, and acidifying and basifying agents that are well known in the prior art, and in amounts that are sufficient to obtain the desired presentation form, in particular a more or less thickened lotion, a gel, an emulsion or a cream.
  • the composition can optionally be used in a form pressurized as an aerosol or vaporized from a pump-dispenser bottle.
  • the peptide prefferably be used in combination with compounds for further improving the activity on hair regrowth and/or on slowing down hair loss, which have already been described for this activity.
  • nicotinic acid esters in particular including tocopheryl nicotinate, benzyl nicotinate and C 1 -C 6 alkyl nicotinates such as methyl or hexyl nicotinate;
  • pyrimidine derivatives such as 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine also known as “Minoxidil” and as described in U.S. Pat. No. 4,139,619;
  • OH-radical scavengers such as dimethylsulfoxide
  • peptides such as, for example, the tripeptide Lys-Pro-Val;
  • microorganism extracts particularly bacterial extracts
  • phospholipids such as lecithin, linoleic acid, linolenic acid, salicylic acid and derivatives thereof described in French patent FR 2 581 542, for instance salicylic acid derivatives bearing an alkyl radical containing from 2 to 12 carbon atoms in position 5 of the benzene ring, hydroxycarboxylic or ketocarboxylic acids and esters thereof, lactones and the corresponding salts thereof, carotenoids, eicosatetraenoic and eicosatrienoic acids or esters and amides thereof, vitamin D and derivatives thereof.
  • phospholipids such as lecithin, linoleic acid, linolenic acid, salicylic acid and derivatives thereof described in French patent FR 2 581 542, for instance salicylic acid derivatives bearing an alkyl radical containing from 2 to 12 carbon atoms in position 5 of the benzene ring, hydroxycarboxylic or ketocarboxylic acids and esters thereof, lac
  • the cosmetic composition according to the invention can be applied to the alopecic regions of the scalp and hair of an individual, and is optionally left in contact for several hours and is optionally to be rinsed out.
  • the cosmetic composition containing an effective amount of at least one metalloprotease inhibitor can be applied to the hair and the scalp in the evening, kept in contact throughout the night and optionally shampooed out in the morning. These applications can be repeated daily for one or more months depending on the individual.
  • a subject of the present invention is also a cosmetic process for treating the hair and/or the scalp, characterized in that it consists in applying a cosmetic composition containing an effective amount of at least one metalloprotease inhibitor to the hair and/or the scalp, in leaving this composition in contact with the hair and/or the scalp, and optionally in rinsing it off.
  • the treatment process has the characteristics of a cosmetic process since it improves the aesthetics of the hair by making it more vigorous and making it look better.
  • An example of a daily lotion is as follows: TIMP-1 0.01 g TIMP-2 0.01 g 2,4 Diaminopyrimidine 3-oxide 0.75 g 95° ethanol 30 g Fragrance qs Dyes qs Demineralized water qs 100 g

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A method for inducing and/or stimulating the growth of hair and/or slowing down hair loss comprising administering an effective amount of at least one metalloprotease inhibitor or any functional biological equivalent thereof and an acceptable carrier therefor.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of copending U.S. patent application Ser. No. 10/677,284, filed Oct. 3, 2003, which is a continuation of U.S. patent application Ser. No. 09/700,195, filed Feb. 20, 2001, now U.S. Pat. No. 6,645,477, both incorporated by reference herein in their entireties and relied upon, application Ser. No. 09/700,195 being the U.S. national phase of International Application No. PCT/FR99/01124, filed May 11, 1999, published as WO99/58101 on Nov. 18, 1999, and claiming the priority of Application No. 98/05968, filed May 12, 1998 in France.
  • The present invention relates to the use, in or for the preparation of a composition, as active principle in a physiologically acceptable medium, of an effective amount of at least one metalloprotease inhibitor, or of any functional biological equivalent, which is intended to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • In humans, the growth and renewal of the hair are mainly determined by the activity of the hair follicles and by their dermo-epidermal environment. Their activity is cyclic and essentially comprises three phases, i.e. the anagenic phase, the catagenic phase and the telogenic phase.
  • The active anagenic phase or growth phase, which lasts for several years and during which the hair gets longer, is followed by a very short and transient catagenic phase which lasts a few weeks, and then comes a rest phase, known as the telogenic phase, which lasts a few months.
  • At the end of the rest period, the hair falls out and another cycle begins. The head of hair is thus under constant renewal, and out of the approximately 150,000 hairs which make up a head of hair, at any given moment, approximately 10% of them are at rest and will thus be replaced within a few months.
  • In a large number of cases, early hair loss occurs in individuals who are genetically predisposed, and it usually affects men. This more particularly concerns androgenetic or androgenic or even androgenogenetic alopecia.
  • This alopecia is essentially due to a disruption in hair renewal which leads, in a first stage, to an acceleration of the frequency of the cycles, at the expense of the quality of the hair and then at the expense of its quantity. A gradual depletion of the head of hair takes place by regression of the so-called “terminal” hairs at the downy stage. Regions are preferentially affected, in particular the temples or frontal bulbs and the back of the head in men, while in women diffuse alopecia of the vertex is observed.
  • Substances for suppressing or reducing alopecia, and in particular for inducing or stimulating hair growth or reducing hair loss, have been sought for many years in the cosmetics and pharmaceutical industries.
  • Admittedly, in this respect, a large number of very diverse active compounds have already been proposed, such as, for example, 2,4-diamino-6-piperidinopyrimidine 3-oxide or “Minoxidil” described in U.S. Pat. No. 4,596,812, or the many derivatives thereof, such as those described, for example, in patent applications EP 0 353 123, EP 0 356 271, EP 0 408 442, EP 0 522 964, EP 0 420 707, EP 0 459 890 and EP 0 519 819. Mention may also be made of 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine and its derivatives, which are described more particularly in U.S. Pat. No. 4,139,619.
  • However, it would generally still be advantageous and useful to be able to provide active compounds other than those already known.
  • Now, after considerable research conducted in this matter, the Applicant has just discovered that a metalloprotease inhibitor, or any functional biological equivalent, makes it possible to induce and/or stimulate the growth of head hair or other hairs, and/or to reduce their loss in an effective manner.
  • Metalloproteases (MMPs) are members of a family of proteolitic enzymes (endoproteases) which contain a zinc atom co-ordinated to 3 cysteine residues and one methionine residue in their active site and which degrade the macromolecular components of the extracellular matrix and the basal sheets at neutral pH (collagen, elastin, etc.). These enzymes, which are very widely distributed in the living world, are present, but weakly expressed, in normal physiological situations such as organ growth and tissue renewal. However, their overexpression in man and their activation are associated with many processes which involve the destruction and remodelling of the matrix. This entails, for example, an uncontrolled resorption of the extracellular matrix.
  • Metalloproteases are produced and secreted in an inactive zymogenic form (pro-enzyme). These zymogenic forms are then activated in the extracellular environment by the removal of a propeptide region. The members of this family can activate each other.
  • Regulation of the activity of MMPs thus takes place at the level of the expression of the genes (transcription and translation), at the level of the activation of the zymogenic form, or at the level of the local control of the active forms.
  • The main regulators of the activity of MMPs are the tissue inhibitors of metalloproteases, or TIMPs. However, the expression of MMPs is also modulated by growth factors, cytokines, oncogenic products (ras, jun) or matrix constituents.
  • The metalloprotease family consists of several well-defined groups based on their resemblances in terms of substrate specificity and structure (see Woessner J. F., Faseb Journal, vol. 5, 1991, 2145). Among these groups, mention may be made of collagenases intended to degrade fibrillar collagens (MMP-1 or interstitial collagenase, MMP-8 or neutrophil collagenase, and MMP-13 or collagenase 3), gelatinases which degrade type IV collagen or any form of denatured collagen (MMP-2 or gelatinase A (72 kDa), MMP-9 or gelatinase B (92 kDa)), stromelysins whose broad spectrum of activity applies to extracellular matrix proteins such as glycoproteins (fibronectin, laminin), proteoglycans, etc. or alternatively membrane metalloproteases.
  • The Applicant has now discovered that metalloproteases are present in the internal structures of hair follicles, namely in the inner epithelial sheath (IRS). In particular, MMP-9 is found in the IRS.
  • Now, it is known that in the course of the hair cycle, hair follicles pass from a low-level location in the dermis in the anagenic phase, to a high-level location in the dermis during the telogenic phase. This movement should be accompanied by a change in the extracellular matrix which allows the migration of the follicle, this change possibly being due to an expression of the MMPs, bringing about a controlled degradation of the said extracellular matrix. It is at the end of the telogenic phase that hair loss occurs. However, it is also known that cytokines and growth factors have an influence on the hair cycle. For example, epidermal growth factor (EGF) promotes the in vitro transition from the anagenic phase to the catagenic phase (formation of a “club” structure characteristic of the catagenic phase), this being the phase which precedes the loss of the head hairs or other hairs. It is also known, as the Applicant has demonstrated, that there is an inflammatory phase in alopecia.
  • The Applicant has shown that the MMPs and particularly MMP-9, can be induced by interleukin-1 and/or EGF, in particular in the fibroblasts of the dermal papillae.
  • The advantage of reducing the expression of MMPs in the scalp in order to slow down or inhibit the degradation of the perifollicular matrix and thus to slow down or even prevent hair loss may thus be appreciated.
  • The Applicant thus proposes the use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • Thus, the invention relates to the use, in or for the preparation of a composition, of an effective amount of at least one metalloprotease inhibitor or of any functional biological equivalent, which is intended to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • The expression “functional biological equivalent” means any molecule which is functionally equivalent in terms of biological function, at least one of the components of which may have been changed for an equivalent component.
  • Examples which may be mentioned are peptides, one biological equivalent of which may be a peptide in which at least one amino acid residue has been replaced with another amino acid having a similar hydropathic index.
  • The expression “metalloprotease inhibitor” means any molecule capable of regulating the activity of MMPs either at the level of the expression of the genes (transcription and translation) or at the level of the activation of the zymogenic form of MMPs, or alternatively at the level of the local control of the active forms.
  • The main regulators of the activity of MMPs are natural molecules present in the tissues, known as tissue inhibitors of metalloproteases, or TIMPs.
  • However, these inhibitors may also be known chemical molecules such as, for example, hydroxamic acid derivatives, cation-chelating agents, growth factors, cytokines, oncogenic products (ras, jun) or matrix constituents.
  • According to the invention, tissue inhibitors of metalloproteases (TIMPs) such as, for example, the peptides known in the prior art under the names TIMP-1, TIMP-2, TIMP-3 and TIMP-4 (Woessner J. F., Faseb Journal, 1991) are preferably used.
  • Thus, the invention relates more particularly to the use, in or for the preparation of a composition, of an effective amount of at least one tissue inhibitor of metalloproteases (TIMP) or of any functional biological equivalent, the inhibitor or the composition being intended to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • The peptides known in the prior art under the names TIMP-1, TIMP-2, TIMP-3 and TIMP-4 are preferably used according to the invention as tissue inhibitors of metalloproteases.
  • Needless to say, according to the invention, the metalloprotease inhibitors can be used alone or as a mixture.
  • It may be the case that, for reasons of resistance to degradation, it is necessary according to the invention to use a protected form of the metalloprotease inhibitor. The form of the protection should obviously be a biologically compatible form. Many biologically compatible forms of protection may be envisaged, such as, for example, acylation or acetylation of the amino-terminal end or amidation of the carboxy-terminal end.
  • Thus, the invention relates to a use as defined above, characterized in that the metalloprotease inhibitor is in a protected or unprotected form.
  • A protection based either on the acylation or acetylation of the amino-terminal end, or on the amidation of the carboxy-terminal end, or alternatively on both approaches, is preferably used according to the invention.
  • Among the chemical inhibitors which may be mentioned are thiols and hydroxamates.
  • The amount of metalloprotease inhibitor which can be used according to the invention obviously depends on the desired effect and should be in an amount which is effective to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss.
  • By way of example, the amount of metalloprotease inhibitor which can be used according to the invention may range, for example from 0.01% to 5% and preferably from 0.05% to 2% relative to the total weight of the composition.
  • The composition is preferably a cosmetic composition.
  • The composition according to the invention can be administered enterally or parenterally. Preferably, via the parenteral route, the composition is administered topically.
  • The physiologically acceptable medium in which the peptide is used according to the invention may be anhydrous or aqueous. The expression “anhydrous medium” means a solvent medium containing less than 1% water. This medium may consist of a solvent or a mixture of solvents chosen more particularly from C2-C4 lower alcohols such as ethyl alcohol, alkylene glycols such as propylene glycol, and alkylene glycol alkyl ethers or dialkylene glycol alkyl ethers, the alkyl or alkylene radicals of which contain from 1 to 4 carbon atoms. The expression “aqueous medium” means a medium consisting of water or of a mixture of water and another physiologically acceptable solvent, chosen in particular from the organic solvents mentioned above. In this last case, when these other solvents are present, they represent approximately 5% to 95% by weight of the composition.
  • It is possible for the physiologically acceptable medium to contain other adjuvants usually used in cosmetics, such as surfactants, thickeners or gelling agents, cosmetic agents, preserving agents, and acidifying and basifying agents that are well known in the prior art, and in amounts that are sufficient to obtain the desired presentation form, in particular a more or less thickened lotion, a gel, an emulsion or a cream. The composition can optionally be used in a form pressurized as an aerosol or vaporized from a pump-dispenser bottle.
  • It is also possible for the peptide to be used in combination with compounds for further improving the activity on hair regrowth and/or on slowing down hair loss, which have already been described for this activity.
  • Among the latter compounds, mention may be made more particularly, in a non-limiting manner, of:
  • nicotinic acid esters, in particular including tocopheryl nicotinate, benzyl nicotinate and C1-C6 alkyl nicotinates such as methyl or hexyl nicotinate;
  • pyrimidine derivatives, such as 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine also known as “Minoxidil” and as described in U.S. Pat. No. 4,139,619;
  • antiandrogenic agents
  • 5-reductase inhibitors;
  • OH-radical scavengers, such as dimethylsulfoxide;
  • peptides such as, for example, the tripeptide Lys-Pro-Val;
  • microorganism extracts, particularly bacterial extracts;
  • plant extracts.
  • Other compounds can also be added to the above list, namely, for example, phospholipids such as lecithin, linoleic acid, linolenic acid, salicylic acid and derivatives thereof described in French patent FR 2 581 542, for instance salicylic acid derivatives bearing an alkyl radical containing from 2 to 12 carbon atoms in position 5 of the benzene ring, hydroxycarboxylic or ketocarboxylic acids and esters thereof, lactones and the corresponding salts thereof, carotenoids, eicosatetraenoic and eicosatrienoic acids or esters and amides thereof, vitamin D and derivatives thereof.
  • The cosmetic composition according to the invention can be applied to the alopecic regions of the scalp and hair of an individual, and is optionally left in contact for several hours and is optionally to be rinsed out. For example, the cosmetic composition containing an effective amount of at least one metalloprotease inhibitor can be applied to the hair and the scalp in the evening, kept in contact throughout the night and optionally shampooed out in the morning. These applications can be repeated daily for one or more months depending on the individual.
  • Thus, a subject of the present invention is also a cosmetic process for treating the hair and/or the scalp, characterized in that it consists in applying a cosmetic composition containing an effective amount of at least one metalloprotease inhibitor to the hair and/or the scalp, in leaving this composition in contact with the hair and/or the scalp, and optionally in rinsing it off.
  • The treatment process has the characteristics of a cosmetic process since it improves the aesthetics of the hair by making it more vigorous and making it look better.
  • Examples will now be given by way of illustration, which should not in any way limit the scope of the invention.
    • EXAMPLE I
  • An example of a daily lotion is as follows:
    TIMP-1 0.01 g
    TIMP-2 0.01 g
    2,4 Diaminopyrimidine 3-oxide 0.75 g
    95° ethanol 30 g
    Fragrance qs
    Dyes qs
    Demineralized water qs 100 g
    • EXAMPLE 2
  • An example of a liposomal gel is as follows:
    Natipide II1 (i.e. 2 g of phospholipids) 10 g
    TIMP-2 0.025 g
    Carbomer 0.25 g
    Triethanolamine qs pH = 7
    Preserving agents qs
    Demineralized water qs 100 g

    1Water/Alcohol/Lecithin mixture from the company Nattermann

Claims (20)

1. A method for inducing and/or stimulating the growth of hair and/or slowing hair loss comprising applying to the hair and/or the scalp of an individual in need thereof, a topical composition comprising an effective amount of at least one metalloprotease inhibitor other than chelating calcium ions and growth factors, in a physiologically acceptable medium.
2. A method for inducing and/or stimulating the growth of hair and/or slowing hair loss comprising applying to the hair and/or the scalp of an individual in need thereof, a topical composition comprising an effective amount of at least one metalloprotease inhibitor selected from the group consisting of tissue inhibitors, cytokines, oncogenic products, matrix inhibitors, and chemical inhibitors other than chelating calcium ions, in a physiologically acceptable medium.
3. A method according to claim 2, wherein the metalloprotease inhibitor is a chemical inhibitor or a tissue inhibitor of metalloproteases.
4. A method for inducing and/or stimulating the growth of hair and/or slowing hair loss comprising applying to the hair and/or the scalp of an individual in need thereof, a topical composition comprising at least one chemical inhibitor of metalloproteases other than chelating calcium ions, and a physiologically acceptable medium.
5. A method according to claim 4, wherein the chemical inhibitor is a thiol or a hydroxamate.
6. The method according to claim 1, wherein said at least one inhibitor is present in an amount of between 0.01% and 5% relative to the total weight of the composition.
7. The method according to claim 2, wherein said at least one inhibitor is present in an amount of between 0.01% and 5% relative to the total weight of the composition.
8. The method according to claim 3, wherein said at least one inhibitor is present in an amount of between 0.01% and 5% relative to the total weight of the composition.
9. The method according to claim 4, wherein said at least one inhibitor is present in an amount of between 0.01% and 5% relative to the total weight of the composition.
10. The method according to claim 5, wherein said at least one inhibitor is present in an amount of between 0.01% and 5% relative to the total weight of the composition.
11. The method according to claim 1, wherein said at least one inhibitor is present in an amount of between 0.05% and 2% relative to the total weight of the composition.
12. The method according to claim 2, wherein said at least one inhibitor is present in an amount of between 0.05% and 2% relative to the total weight of the composition.
13. The method according to claim 3, wherein said at least one inhibitor is present in an amount of between 0.05% and 2% relative to the total weight of the composition.
14. The method according to claim 4, wherein said at least one inhibitor is present in an amount of between 0.05% and 2% relative to the total weight of the composition.
15. The method according to claim 5, wherein said at least one inhibitor is present in an amount of between 0.05% and 2% relative to the total weight of the composition.
16. The method according to claim 1, further comprising leaving said composition in contact with the hair and/or the scalp for a sufficient time and optionally rinsing said composition from the treated area.
17. The method according to claim 2, further comprising leaving said composition in contact with the hair and/or the scalp for a sufficient time and optionally rinsing said composition from the treated area.
18. The method according to claim 3, further comprising leaving said composition in contact with the hair and/or the scalp for a sufficient time and optionally rinsing said composition from the treated area.
19. The method according to claim 4, further comprising leaving said composition in contact with the hair and/or the scalp for a sufficient time and optionally rinsing said composition from the treated area.
20. The method according to claim 5, further comprising leaving said composition in contact with the hair and/or the scalp for a sufficient time and optionally rinsing said composition from the treated area.
US11/331,011 1998-05-12 2006-01-13 Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss Abandoned US20060105006A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/331,011 US20060105006A1 (en) 1998-05-12 2006-01-13 Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR9805968A FR2778558B1 (en) 1998-05-12 1998-05-12 USE OF A METALLOPROTEINASE INHIBITOR TO INDUCE AND / OR STIMULATE THE GROWTH OF HAIR OR HAIR AND / OR TO STOP THE FALL
FR98/05968 1998-05-12
US09/700,195 US6645477B1 (en) 1998-05-12 1999-05-11 Use of metalloprotinease inhibitors to inducing and/or stimulating growth of hair or hair or hairs and/or for slowing down their loss
PCT/FR1999/001124 WO1999058101A1 (en) 1998-05-12 1999-05-11 Use of metalloprotinease inhibitors for inducing and/or stimulating growth of hair or hairs and/or for slowing down their loss
US10/677,284 US20040071647A1 (en) 1998-05-12 2003-10-03 Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss
US11/331,011 US20060105006A1 (en) 1998-05-12 2006-01-13 Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/677,284 Continuation US20040071647A1 (en) 1998-05-12 2003-10-03 Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss

Publications (1)

Publication Number Publication Date
US20060105006A1 true US20060105006A1 (en) 2006-05-18

Family

ID=9526261

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/700,195 Expired - Fee Related US6645477B1 (en) 1998-05-12 1999-05-11 Use of metalloprotinease inhibitors to inducing and/or stimulating growth of hair or hair or hairs and/or for slowing down their loss
US10/677,284 Abandoned US20040071647A1 (en) 1998-05-12 2003-10-03 Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss
US11/331,011 Abandoned US20060105006A1 (en) 1998-05-12 2006-01-13 Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/700,195 Expired - Fee Related US6645477B1 (en) 1998-05-12 1999-05-11 Use of metalloprotinease inhibitors to inducing and/or stimulating growth of hair or hair or hairs and/or for slowing down their loss
US10/677,284 Abandoned US20040071647A1 (en) 1998-05-12 2003-10-03 Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss

Country Status (10)

Country Link
US (3) US6645477B1 (en)
EP (1) EP1076549B1 (en)
JP (1) JP3891541B2 (en)
AT (1) ATE275919T1 (en)
AU (1) AU3611299A (en)
CA (1) CA2330807C (en)
DE (1) DE69920205T2 (en)
ES (1) ES2229701T3 (en)
FR (1) FR2778558B1 (en)
WO (1) WO1999058101A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120768A1 (en) * 2006-09-28 2010-05-13 David Steinberg Methods, kits, and compositions for generating new hair follicles and growing hair

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2778558B1 (en) * 1998-05-12 2001-02-16 Oreal USE OF A METALLOPROTEINASE INHIBITOR TO INDUCE AND / OR STIMULATE THE GROWTH OF HAIR OR HAIR AND / OR TO STOP THE FALL
US6803044B1 (en) 1999-03-24 2004-10-12 Zengen, Inc. Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus
US7402559B2 (en) 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
US6800291B1 (en) 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
DE10102784A1 (en) * 2001-01-22 2002-08-01 Henkel Kgaa Cosmetic or pharmaceutical preparations for the treatment of epithelial cover tissue
US6780838B2 (en) 2001-01-29 2004-08-24 Zengen, Inc. Compounds for treating fungal pathologies of the oral cavity
US6894028B2 (en) 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
US7115574B2 (en) 2001-12-10 2006-10-03 Zengen, Inc. System and method for support legacy operating system booting in a legacy-free system
US6939846B2 (en) 2001-12-17 2005-09-06 Zengen, Inc. Use of a polypeptide for treatment of pruritis in animals
US7834210B2 (en) * 2006-08-04 2010-11-16 Bioderm Research Hair loss prevention by natural amino acid and peptide complexes
US20050180940A1 (en) * 2004-02-17 2005-08-18 Puma Jeffrey P. Protect against hair loss
ES2330291B1 (en) 2008-02-29 2010-10-18 Lipotec Sa USEFUL PEPTIDES IN THE TREATMENT OF SKIN, MUCOSAS AND / OR LEATHER HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS.
ES2349972B1 (en) 2009-02-16 2011-11-24 Lipotec, S.A. USEFUL PEPTIDES IN THE TREATMENT AND / OR CARE OF SKIN, MUCOUSES AND / OR LEATHER LEATHER AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS.
US9763984B2 (en) 2012-12-21 2017-09-19 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
EP3403673B1 (en) * 2016-01-12 2023-10-11 National University Corporation Tokyo Medical and Dental University Composition for preventing or ameliorating loss of hair and graying of hair, and use thereof
CA3030054A1 (en) 2016-07-15 2018-01-18 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
US12133858B2 (en) * 2022-12-16 2024-11-05 Advanced Protein Technologies Corp. Composition for promoting hair growth and improving, preventing, or treating hair loss containing 2′-fucosyllactose as an active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166005A (en) * 1996-08-28 2000-12-26 The Procter & Gamble Company Heterocyclic metalloprotease inhibitors
US6645477B1 (en) * 1998-05-12 2003-11-11 Societe L'oreal S.A. Use of metalloprotinease inhibitors to inducing and/or stimulating growth of hair or hair or hairs and/or for slowing down their loss

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1717019B1 (en) * 1958-12-05 1972-04-27 Henkel & Cie Gmbh Process for the production of highly dispersed sulfur-containing surface-active liquid products
US4814351A (en) * 1987-06-26 1989-03-21 Redken Laboratories, Inc. Scalp treatment
GB8806893D0 (en) 1988-03-23 1988-04-27 Unilever Plc Cosmetic composition
JPH0374318A (en) 1989-08-10 1991-03-28 Katsumi Mizumaki Hair-growing and hair-tonic agent
FR2651125B1 (en) * 1989-08-23 1992-10-02 Roussel Uclaf PHARMACEUTICAL COMPOSITIONS OF THE "WATER PASTE" TYPE.
JPH04224522A (en) * 1990-04-27 1992-08-13 Merck & Co Inc Therapeutic or prophylactic method for alopecia using composition containing fibroblast growth factor
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
JPH06509072A (en) 1991-06-28 1994-10-13 ユニバーシティー、オブ、マイアミ Prevention and treatment of chemotherapy-induced hair loss
JPH0543424A (en) 1991-08-14 1993-02-23 Sansho Seiyaku Co Ltd External agent for use in hair
JP3229643B2 (en) 1992-03-31 2001-11-19 秀興 小川 Hair growth promoter
US6380366B1 (en) * 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
US6028118A (en) 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
US5618925A (en) 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US6025334A (en) 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
KR100499190B1 (en) * 1996-03-29 2006-04-17 교와 핫꼬 고교 가부시끼가이샤 Hair restorer
JPH10279501A (en) * 1997-02-10 1998-10-20 Rohto Pharmaceut Co Ltd Hair growing agent
JP3464591B2 (en) 1997-07-04 2003-11-10 カネボウ株式会社 Hair restoration cosmetics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166005A (en) * 1996-08-28 2000-12-26 The Procter & Gamble Company Heterocyclic metalloprotease inhibitors
US6645477B1 (en) * 1998-05-12 2003-11-11 Societe L'oreal S.A. Use of metalloprotinease inhibitors to inducing and/or stimulating growth of hair or hair or hairs and/or for slowing down their loss

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120768A1 (en) * 2006-09-28 2010-05-13 David Steinberg Methods, kits, and compositions for generating new hair follicles and growing hair
US8252749B2 (en) 2006-09-28 2012-08-28 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair

Also Published As

Publication number Publication date
US6645477B1 (en) 2003-11-11
JP3891541B2 (en) 2007-03-14
DE69920205D1 (en) 2004-10-21
ATE275919T1 (en) 2004-10-15
CA2330807A1 (en) 1999-11-18
DE69920205T2 (en) 2005-09-22
FR2778558B1 (en) 2001-02-16
WO1999058101A1 (en) 1999-11-18
CA2330807C (en) 2007-01-30
FR2778558A1 (en) 1999-11-19
EP1076549A1 (en) 2001-02-21
JP2002514581A (en) 2002-05-21
ES2229701T3 (en) 2005-04-16
AU3611299A (en) 1999-11-29
EP1076549B1 (en) 2004-09-15
US20040071647A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
US20060105006A1 (en) Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss
US7470438B1 (en) Ericacea extracts for combating skin aging
US20080003311A1 (en) Rosmarinus extracts for inhibiting/treating skin aging
US6884425B2 (en) Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor
US20100189675A1 (en) Cosmetic use of an imidopercarboxylic acid derivative as desquamating agent
HUP0302744A2 (en) Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
KR20050084979A (en) Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
US6998129B2 (en) Cosmetic or dermatological composition comprising an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound
US20040005370A1 (en) Composition, in particular cosmetic, containing dhea and/or a chemical or biological precursor or derivative thereof , and a metalloproteinase inhibitors
US20100189709A1 (en) Elastase inhibitor
JP2006131633A (en) Use of urea compound for suppressing aging sign of skin
US8173144B2 (en) Administration of urea compounds for combating signs of cutaneous aging
JP4433364B2 (en) Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one muscle relaxant
JP2009091325A (en) Hair growth agent
JP2005508873A (en) Cosmetic or dermatological composition containing N-acylaminoamide derivative
EA023680B1 (en) Interleukin-1 beta in cosmetic compositions and methods for use thereof
US20050065212A1 (en) Use of at least one 10-hydroxy-2-decenoic acid derivative in compositions for treating the cuteous signs of aging
US20040071798A1 (en) Admixture of extracts of plants of the genus rosmarinus and carotenoids for treating cutaneous symptoms of aging
KR20040107211A (en) Cosmetic Composition for Anti-aging Comprising Scoparone as Active Ingredients

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载